IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 125 filers reported holding IMMUNOVANT INC in Q1 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $65,024,291 | +9693.6% | 1,693,782 | +4739.4% | 1.00% | +8250.0% |
Q2 2023 | $663,950 | +22.3% | 35,000 | 0.0% | 0.01% | +20.0% |
Q1 2023 | $542,850 | -66.3% | 35,000 | -81.1% | 0.01% | -44.4% |
Q3 2021 | $1,609,000 | -17.8% | 185,200 | 0.0% | 0.02% | -30.8% |
Q2 2021 | $1,957,000 | -59.7% | 185,200 | -38.8% | 0.03% | -75.0% |
Q1 2021 | $4,855,000 | – | 302,700 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |